Minerva Neurosciences to Participate in The Stifel 2026 Virtual CNS Forum
Rhea-AI Summary
Minerva Neurosciences (Nasdaq: NERV) will present at The Stifel 2026 Virtual CNS Forum on March 18, 2026 at 8:30 AM ET.
Remy Luthringer, PhD, Executive Chairman & CEO, will deliver the company presentation; a replay will be available on the company’s Investors & Media Events and Presentations webpage for ninety days.
Positive
- None.
Negative
- None.
News Market Reaction – NERV
In the Mar 12 session, NERV gained 5.34%, reflecting a notable positive market reaction. Argus tracked a peak move of +4.8% during that session. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 11 | FY2025 earnings | Negative | -8.1% | Large 2025 GAAP loss and financing details weighed on shares. |
| Mar 4 | Conference participation | Neutral | -0.4% | Standard investor conference appearance had minimal price impact. |
| Jan 26 | KOL event | Positive | +2.5% | KOL event outlining Phase 3 design and unmet need supported a gain. |
| Nov 19 | Board appointment | Positive | +0.0% | New director and funding plans for Phase 3 saw little price reaction. |
| Nov 5 | Q3 2025 earnings | Positive | +4.1% | Financing and FDA alignment for Phase 3 coincided with a price rise. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news reactions mostly aligned with the nature of the events, with positive clinical/financing updates often seeing constructive or stable price responses and one flat reaction to a positive board/financing item.
Over the last few months, Minerva has focused on funding and advancing roluperidone. The company closed an $80.0M upfront private placement with potential additional proceeds up to $120.0M and reported sizeable 2025 losses on Mar 11, 2026. Earlier, a Nov 5, 2025 update highlighted a private placement with $80M gross proceeds and up to $200M via warrants supporting a confirmatory Phase 3 trial. Management also added board expertise for roluperidone and hosted a detailed KOL event. Today’s conference participation fits an ongoing investor‑outreach and clinical‑messaging trajectory.
Key Terms
central nervous system medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
BURLINGTON, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that Remy Luthringer, PhD, Executive Chairman & Chief Executive Officer, will participate in The Stifel 2026 Virtual CNS Forum being held March 17-18, 2026.
| The Stifel 2026 Virtual CNS Forum | |
| Format: | Company presentation |
| Day/Time: | Wednesday, March 18 at 8.30 AM ET |
| Webcast: | Webcast Link: |
| https://event.summitcast.com/view/4Ggc9Rmi4GQpDPGZwDp8g8/DdYPDYEQLLU6kp2AWRS6bu | |
If you are interested in a virtual meeting with the Minerva team during the conference, please reach out to your Stifel representative.
A replay of the presentation will be available on the Company's Investors & Media Events and Presentations webpage for ninety days following the event.
About Minerva Neurosciences
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing product candidates to treat CNS diseases. Minerva is initiating a confirmatory Phase 3 trial with roluperidone for negative symptoms of schizophrenia. For more information, please visit the Company’s website.
Contacts:
Investor inquiries:
Frederick Ahlholm
Chief Financial Officer
Minerva Neurosciences, Inc.
FAhlholm@minervaneurosciences.com
Corey Davis, Ph.D.
LifeSci Advisors, LLC
212-915-2577
cdavis@lifesciadvisors.com
